Last 37 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.27 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 96.22 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 46.27 | 0.61 | 74.30 | 47.72 | 21.18 | 255.62 | 83.44 | 424.61 | 165.42 | 105.93 | 333.48 | 237.98 | 1452.98 | 1241.39 | 1267.78 | 16790.49 | 965.88 | 2234.72 | 2528.15 | 297.76 | 6796.89 |
| — | -99.8% | -11.0% | -88.8% | -87.2% | +141.3% | -75.0% | +78.4% | -88.6% | -91.5% | -73.7% | -98.6% | +50.4% | -44.4% | -49.9% | +5539.0% | -85.8% | -70.8% | -86.1% | -66.9% | +538.4% | |
| P/B Ratio | 1.22 | 50.11 | 1.04 | 0.89 | 0.45 | 1.81 | 1.53 | 2.74 | 1.26 | 1.12 | 1.57 | 0.82 | 57.59 | 38.81 | 18.99 | 12.91 | 16.10 | 23.29 | 32.30 | 56.13 | 61.41 |
| — | +2661.5% | -32.1% | -67.4% | -64.6% | +61.9% | -2.6% | +236.0% | -97.8% | -97.1% | -91.7% | -93.7% | +257.6% | +66.6% | -41.2% | -77.0% | -73.8% | -80.7% | -82.1% | -86.4% | -78.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 55.67 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +597.8% | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.0% | 100.0% | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 60.6% | 78.9% |
| — | 0.0% | -7.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +65.0% | +26.7% | +10.5% | 0.0% | -30.8% | -10.9% | |
| Operating Margin | -5219.1% | -5219.1% | -4437.2% | -4014.6% | -4610.7% | -10930.4% | -4553.0% | -15202.4% | -10819.0% | -5250.5% | -7530.6% | -8989.5% | -5468.4% | -7643.0% | -5934.3% | -133066.7% | -5588.6% | -6577.0% | -4882.6% | 525.5% | -8095.5% |
| — | +52.3% | +2.5% | +73.6% | +57.4% | -108.2% | +39.5% | -69.1% | -97.8% | +31.3% | -26.9% | +93.2% | +2.2% | -16.2% | -21.5% | -25422.9% | +31.0% | -103.3% | -15.1% | -95.3% | -1226.6% | |
| Net Margin | -4646.1% | -4646.1% | -4168.6% | -3720.8% | -4307.7% | -8340.6% | -4262.9% | -14311.9% | -10047.1% | -4750.5% | -6376.5% | -8142.1% | -5775.4% | -7450.4% | -5678.8% | -165750.0% | -5664.1% | -6727.0% | 2623.6% | -504.8% | -16003.8% |
| — | +44.3% | +2.2% | +74.0% | +57.1% | -75.6% | +33.1% | -75.8% | -74.0% | +36.2% | -12.3% | +95.1% | -2.0% | -10.8% | -316.5% | -32734.8% | +64.6% | +0.4% | +129.4% | +6.7% | -2016.9% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -66.3% | -214.7% | -13.7% | -16.2% | -20.5% | -13.9% | -17.9% | -20.8% | -17.6% | -11.9% | -7.3% | -12.3% | -45.8% | -46.0% | -19.5% | -27.9% | -21.4% | -16.3% | 8.9% | -21.5% | -31.8% |
| — | -1448.8% | +23.6% | +22.3% | -16.8% | -16.6% | -146.5% | -68.4% | +61.6% | +74.2% | +62.8% | +55.8% | -113.9% | -182.6% | -318.0% | -29.7% | +32.8% | +31.4% | +128.4% | +59.6% | +22.1% | |
| ROA | -54.6% | -204.5% | -12.8% | -14.6% | -18.0% | -11.4% | -14.0% | -16.8% | -14.9% | -10.5% | -6.6% | -10.6% | -29.8% | -33.4% | -14.8% | -22.7% | -18.5% | -14.2% | 7.1% | -15.6% | -19.8% |
| — | -1696.8% | +8.4% | +13.1% | -20.6% | -7.9% | -111.6% | -58.8% | +49.9% | +68.4% | +55.4% | +53.4% | -60.7% | -135.5% | -308.0% | -45.5% | +6.3% | -0.8% | +142.0% | +32.2% | +4.6% | |
| ROIC | -124.0% | -458240.9% | -152.9% | -47.5% | -39.5% | -34.4% | -28.6% | -24.0% | -21.2% | -14.2% | -9.0% | -18.8% | — | — | — | -246.8% | -138.2% | -113.8% | -107.8% | 125.7% | -117.5% |
| — | -1330348.1% | -434.7% | -97.5% | -86.6% | -142.6% | -217.1% | -27.6% | — | — | — | +92.4% | — | — | — | -296.2% | -17.5% | -20.8% | -75.4% | -95.4% | -174.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.01 | 0.02 |
| — | — | — | — | — | -66.8% | -33.9% | -21.2% | — | — | — | — | — | — | — | — | — | -99.9% | -99.4% | -99.2% | -97.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.03 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -59.8% | — | |
| Current Ratio | 12.53 | 12.53 | 20.86 | 12.53 | 8.87 | 7.60 | 4.47 | 4.35 | 5.81 | 7.13 | 13.02 | 12.73 | 2.72 | 3.60 | 4.39 | 4.10 | 6.44 | 7.60 | 7.06 | 3.43 | 3.63 |
| — | +64.9% | +367.0% | +188.2% | +52.8% | +6.6% | -65.7% | -65.8% | +113.9% | +97.9% | +196.4% | +210.8% | -57.8% | -52.6% | -37.8% | +19.3% | +77.6% | +240.8% | +6.3% | -14.4% | -14.3% | |
| Quick Ratio | 12.53 | 12.53 | 20.86 | 12.53 | 8.87 | 7.60 | 4.47 | 4.35 | 5.81 | 7.13 | 13.02 | 12.73 | 2.71 | 3.59 | 4.39 | 4.10 | 6.44 | 7.60 | 7.06 | 3.04 | 3.24 |
| — | +64.9% | +367.0% | +188.2% | +52.8% | +6.6% | -65.7% | -65.8% | +114.6% | +98.5% | +196.4% | +210.8% | -58.0% | -52.7% | -37.8% | +34.9% | +98.7% | +264.3% | +12.7% | -17.2% | -17.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -3.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 37 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VYNE stock.
VYNE Therapeutics Inc.'s current P/E is -1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
VYNE Therapeutics Inc.'s current operating margin is -5219.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking VYNE Therapeutics Inc.'s business trajectory between earnings reports.